Tivic Health Systems, Inc.
For the period ended Dec 31, 2025. Filed Mar 30, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 30, 2026
VBIO$0.54+6.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
As of December 31, 2025 and 2024
(in thousands, except share and per share data)
| 2025 | 2024 | |
|---|---|---|
| ASSETS | ||
| Current assets | ||
| Cash and cash equivalents | $12,645 | $2,002 |
| Prepaid expenses and other current assets | 346 | 240 |
| Current assets of discontinued operations | 15 | 397 |
| Total current assets | 13,006 | 2,639 |
| Property and equipment, net | 12,641 | 2 |
| Deferred offering costs | 136 | 49 |
| Licensed technology, net | 2,243 | — |
| Goodwill | 3,457 | — |
| Other assets | 124 | — |
| Non-current assets of discontinued operations | — | 117 |
| TOTAL ASSETS | $31,607 | $2,807 |
| LIABILITIES, TEMPORARY EQUITY AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities | ||
| Accounts payable | $264 | $125 |
| Other accrued expenses | 376 | 132 |
| Current liabilities of discontinued operations | 6 | 15 |
| Total current liabilities | 646 | 272 |
| Convertible note payable, net | 6,454 | — |
| Derivative liability | 292 | — |
| Other non-current liabilities | 48 | — |
| Non-current liabilities of discontinued operations | — | — |
| Total liabilities | 7,440 | 272 |
| COMMITMENTS AND CONTINGENCIES (Note 9) | ||
| Temporary equity | ||
| Series B preferred stock, par value $0.001, 8,400 shares authorized and 2,155 shares issued and outstanding as of December 31, 2025, and no shares issued and outstanding as of December 31, 2024 | 1,379 | — |
| Series C preferred stock, par value $0.001, 75,400 shares authorized and 12,000 shares issued and outstanding as of December 31, 2025, and no shares issued and outstanding as of December 31, 2024 | 5,991 | — |
| STOCKHOLDERS' EQUITY | ||
| Preferred stock, $0.0001 par value, 10,000,000 shares authorized; 403 shares issued and outstanding as of December 31, 2025, and no shares issued and outstanding as of December 31, 2024 | — | — |
| Common stock, $0.0001 par value, 200,000,000 shares authorized; 2,525,778 and 556,902 shares issued and outstanding as of December 31, 2025, and December 31, 2024, respectively | 2 | 1 |
| Additional paid in capital | 69,392 | 46,075 |
| Accumulated deficit | (52,597) | (43,541) |
| Total Stockholders’ equity | 16,797 | 2,535 |
| TOTAL LIABILITIES, TEMPORARY EQUITY AND STOCKHOLDERS' EQUITY | $31,607 | $2,807 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.